Edition:
India

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

4,324.00GBp
16 Jul 2018
Change (% chg)

-16.00 (-0.37%)
Prev Close
4,340.00
Open
4,346.00
Day's High
4,369.50
Day's Low
4,309.00
Volume
1,530,054
Avg. Vol
3,629,279
52-wk High
4,420.00
52-wk Low
2,940.50

Latest Key Developments (Source: Significant Developments)

Takeda Pharmaceutical Announces Statement Regarding US FTC Clearance
Tuesday, 10 Jul 2018 

July 10 (Reuters) - Takeda Pharmaceutical Company Ltd <4502.T>::STATEMENT REGARDING US FTC CLEARANCE.TAKEDA RECEIVES CLEARANCE FROM UNITED STATES FEDERAL TRADE COMMISSION FOR PROPOSED ACQUISITION OF SHIRE PLC.  Full Article

Takeda Pharm CEO Weber Says Neuroscience Will Continue To Be A Core Area
Tuesday, 8 May 2018 

May 8 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T> Chief Executive Officer Christophe Weber::NEUROSCIENCE WILL CONTINUE TO BE A CORE AREA.JOBS COULD BE IMPACTED.  Full Article

GSK New R&D Head Barron Says Work To Do To Translate DPU Research Into Drugs
Wednesday, 25 Apr 2018 

April 25 (Reuters) - Glaxosmithkline ::NEW RESEARCH AND DEVELOPMENT HEAD BARRON SAYS WORK TO DO TO TRANSLATE RESEARCH AT DPU UNITS INTO DRUGS.  Full Article

GSK Expecting Shingrix Sales For Year To Be Above 400 Million Stg
Wednesday, 25 Apr 2018 

April 25 (Reuters) - GlaxoSmithKline ::CFO SAYS EXPECTING SHINGRIX SALES FOR YEAR TO BE AT THE SAME RATE AS IN Q1, OR 400 MILLION STG+ FOR 2018.  Full Article

Takeda Says Notes Statement By Shire Regarding Revised Proposal, Deadline Extension
Wednesday, 25 Apr 2018 

April 25 (Reuters) - Japan's Takeda Pharmaceutical Co Ltd <4502.T>::SAYS NOTES STATEMENT BY SHIRE PLC REGARDING REVISED PROPOSAL AND EXTENSION OF PUSU DEADLINE TO MAY 8, 2018.SAYS INTENDS TO MAINTAIN ITS WELL-ESTABLISHED DIVIDEND POLICY AND INVESTMENT GRADE CREDIT RATING.  Full Article

Shire announces Takeda's revised proposal of about 49 pounds per share
Wednesday, 25 Apr 2018 

April 24 (Reuters) - Shire Plc ::SHIRE ANNOUNCES REVISED PROPOSAL AND EXTENSION OF PUSU DEADLINE TO 8 MAY 2018.INDICATED TO TAKEDA WOULD BE WILLING TO RECOMMEND REVISED PROPOSAL TO SHAREHOLDERS SUBJECT TO SATISFACTORY RESOLUTION OF OTHER TERMS OF POSSIBLE OFFER.SATISFACTORY RESOLUTION OF OTHER TERMS OF POSSIBLE OFFER, INCLUDE COMPLETION OF RECIPROCAL DUE DILIGENCE BY SHIRE ON TAKEDA.REVISED PROPOSAL COMPRISES 0.839 NEW TAKEDA SHARES AND US$30.33 IN CASH FOR EACH SHIRE ORDINARY SHARE.REVISED PROPOSAL IMPLIES AN EQUIVALENT VALUE OF APPROXIMATELY £49 PER SHIRE ORDINARY SHARE.REVISED PROPOSAL COMPRISING OF £27.26 IN NEW TAKEDA SHARES; AND £21.75 IN CASH.REVISED PROPOSAL IS EQUIVALENT TO A VALUE OF APPROXIMATELY £46 BILLION FOR ENTIRE ISSUED AND TO BE ISSUED SHARE CAPITAL OF COMPANY.CO SHAREHOLDERS WOULD BE ENTITLED TO ANY DIVIDENDS ANNOUNCED BY SHIRE IN ORDINARY COURSE PRIOR TO COMPLETION OF POSSIBLE TRANSACTION.ON DEAL COMPLETION, SHIRE SHAREHOLDERS WOULD OWN APPROXIMATELY 50 PER CENT.OF THE ENLARGED TAKEDA AND THE NEW TAKEDA SHARES WILL BE LISTED IN JAPAN AND IN US THROUGH AN ADR PROGRAM.  Full Article

Shire Says Received Revised Proposal From Takeda On Possible Offer, Says Considering Its Position
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Shire Plc ::SHIRE PLC: STATEMENT RE REVISED PROPOSAL.RECEIVED A REVISED PROPOSAL FROM TAKEDA REGARDING A POSSIBLE OFFER FOR COMPANY ON 24 APRIL 2018.BOARD IS CONSIDERING ITS POSITION.CAN BE NO CERTAINTY THAT ANY FIRM OFFER FOR COMPANY WILL BE MADE NOR AS TO TERMS ON WHICH ANY FIRM OFFER MIGHT BE MADE.  Full Article

Takeda Is Said To Near Preliminary Agreement To Buy Shire- Bloomberg
Tuesday, 24 Apr 2018 

April 24 (Reuters) - :TAKEDA IS SAID TO NEAR PRELIMINARY AGREEMENT TO BUY SHIRE - BLOOMBERG, CITING SOURCES.  Full Article

Shire Says Considering Position With Respect To Fourth Proposal From Takeda
Friday, 20 Apr 2018 

April 20 (Reuters) - Shire Plc ::SHIRE PLC - STATEMENT RE PROPOSAL FROM TAKEDA PHARMACEUTICAL COMPANY LIMITED ("TAKEDA").SHIRE PLC - BOARD OF SHIRE IS CONSIDERING ITS POSITION WITH RESPECT TO FOURTH PROPOSAL AND WILL ISSUE A FURTHER ANNOUNCEMENT IN DUE COURSE.SHIRE PLC - CONFIRMS IT HAS RECEIVED A FOURTH PROPOSAL FROM TAKEDA ON 20 APRIL 2018 REGARDING A POSSIBLE OFFER FOR COMPANY.  Full Article

Shire Rejects Third Proposal From Takeda To Buy Out Co
Thursday, 19 Apr 2018 

April 19 (Reuters) - Shire Plc ::NOTES ANNOUNCEMENT MADE BY TAKEDA.BOARD HAS SINCE RECEIVED TWO FURTHER PROPOSALS.SECOND PROPOSAL COMPRISED £28.75 PER SHARE IN NEW TAKEDA SHARES, TO BE LISTED IN JAPAN AND IN US; £16.75 PER SHARE IN CASH.SECOND DEAL PROPOSAL REPRESENTS A POTENTIAL VALUE OF £45.50 PER SHARE.SECOND DEAL PROPOSAL REPRESENTS A POTENTIAL VALUE OF APPROXIMATELY £43 BILLION FOR TOTAL ISSUED AND TO BE ISSUED SHARE CAPITAL OF COMPANY.UNDER SECOND PROPOSAL, BASED ON TAKEDA'S CURRENT MARKET CAP, SHIRE SHAREHOLDERS WOULD OWN APPROXIMATELY 51 PER CENT. OF ENLARGED TAKEDA.THIRD PROPOSAL ALSO COMPRISED £28.75 PER SHARE IN NEW TAKEDA SHARES, TO BE LISTED IN JAPAN AND IN US THROUGH AN ADR LISTING, AND £17.75 PER SHARE IN CASH.BASED ON TAKEDA'S CURRENT MARKET CAPITALISATION, UNDER THIRD PROPOSAL SHIRE SHAREHOLDERS WOULD OWN APPROXIMATELY 51 PER CENT.BOARD MET AGAIN AND THOROUGHLY CONSIDERED THIRD PROPOSAL WITH ITS ADVISERS, UNANIMOUSLY REJECTED IT, CONCLUDING THAT IT CONTINUES TO SIGNIFICANTLY UNDERVALUE CO.THIRD PROPOSAL REPRESENTS POTENTIAL VALUE OF £46.50 PER SHARE, ABOUT £44 BILLION FOR TOTAL ISSUED AND TO BE ISSUED SHARE CAPITAL OF COMPANY.SHIRE'S ADVISERS ENTERED INTO A DIALOGUE WITH TAKEDA'S ADVISERS TO DISCUSS WHETHER A FURTHER, MORE ATTRACTIVE, PROPOSAL MAY BE FORTHCOMING.  Full Article

Photo

Japan's Takeda gains U.S. approval for $62 billion Shire buy

TOKYO Takeda Pharmaceutical Co Ltd on Tuesday said it has received U.S. approval for its $62 billion acquisition of London-listed Shire Plc, taking the Japanese firm one step closer to its goal of becoming a global top 10 drugmaker.